Form 8-K - Current report:
SEC Accession No. 0001601830-24-000009
Filing Date
2024-01-31
Accepted
2024-01-31 16:40:16
Documents
15
Period of Report
2024-01-25
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rxrx-20240125.htm   iXBRL 8-K 25853
2 EX-3.1 a1-25x24amendedbylaws.htm EX-3.1 235697
  Complete submission text file 0001601830-24-000009.txt   431822

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rxrx-20240125.xsd EX-101.SCH 1907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rxrx-20240125_lab.xml EX-101.LAB 24835
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rxrx-20240125_pre.xml EX-101.PRE 13047
16 EXTRACTED XBRL INSTANCE DOCUMENT rxrx-20240125_htm.xml XML 2846
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40323 | Film No.: 24583502
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)